Emtricitabine rilpivirine tenofovir: Difference between revisions
Jump to navigation
Jump to search
| Line 29: | Line 29: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
COMPLERA is a fixed-dose combination of the antiretroviral drugs [[emtricitabine]], [[rilpivirine]] and [[tenofovir disoproxil fumarate]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = COMPLERA (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d637cfab-f1e8-4eb3-a1b3-f85ca3bec612 | publisher = | date = | accessdate}}</ref> | COMPLERA is a fixed-dose combination of the antiretroviral drugs [[emtricitabine]], [[rilpivirine]] and [[Tenofovir|tenofovir disoproxil fumarate]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = COMPLERA (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d637cfab-f1e8-4eb3-a1b3-f85ca3bec612 | publisher = | date = | accessdate}}</ref> | ||
==References== | ==References== | ||
Revision as of 04:19, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Category
Antiretroviral
US Brand Names
COMPLERA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
COMPLERA is a fixed-dose combination of the antiretroviral drugs emtricitabine, rilpivirine and tenofovir disoproxil fumarate.[1]